<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>Summary of preclinical and clinical evidence on drugs with potential activity against COVID-19.</p>
 </caption>
 <alt-text id="alttext0010">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Drug/indication</th>
    <th>Anti-infective mechanism</th>
    <th>Preclinical and clinical Evidence</th>
    <th>Major safety concerns</th>
    <th>Drug interactions</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="4" align="left">
     <bold>Antivirals with potential activity against SARS-CoV-</bold>2
     <xref rid="tbl1fna" ref-type="table-fn">a</xref>
    </td>
    <td/>
   </tr>
   <tr>
    <td align="left">
     <bold>Lopinavir/ritonavir (LPV/r)</bold>
     <break/>
     <bold>Approved drug combination for HIV infection</bold>
    </td>
    <td align="left">A fixed dose combination medication indicated for the treatment and prevention of HIV/AIDS (HIV-1 Protease inhibitor)</td>
    <td align="left">
     <list list-type="simple" id="ulist0015">
      <list-item id="u0070">
       <label>•</label>
       <p id="p0185">
        <italic>In vitro</italic> and animal studies demonstrated LPV/r activity against/benefit for the treatment of MERS-CoV 2,
        <xref rid="bib9" ref-type="bibr">
         <sup>9</sup>
        </xref>
        <sup>,</sup>
        <xref rid="bib10" ref-type="bibr">
         <sup>10</sup>
        </xref> but more study is need on its 
        <italic>in vitro</italic> &amp; 
        <italic>in vivo</italic> activity against SARS-CoV-2.
        <xref rid="bib9" ref-type="bibr">
         <sup>9</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0075">
       <label>•</label>
       <p id="p0190">A retrospective study reviewed records of hospitalised COVID-19 patients (n = 323) in Tianyou Hospital, Wuhan, China from 8 January to 20 February 2020, and reported that 46% (13/28) of patients receiving LPV/r developed favourable outcomes (full recovery and discharge, progression from critical/severe to non-severe disease status, PCR positive to negative, and/or maintenance of non-severe status).
        <xref rid="bib11" ref-type="bibr">
         <sup>11</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0080">
       <label>•</label>
       <p id="p0195">A retrospective study investigated duration of viral shedding in hospitalised COVID-19 patients (n = 298) in Hubei Province, China, between 31 January 2020 and 9 March 2020, reporting that median duration of viral shedding was shorter in the LPV/r treatment group (n = 78) than that in no LPV/r treatment group (n = 42) (median, 22 days vs 28.5 days, p = 0.02). Only earlier administration of LPV/r treatment (≤10 days from symptom onset) could shorten the duration of viral shedding.
        <xref rid="bib12" ref-type="bibr">
         <sup>12</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0085">
       <label>•</label>
       <p id="p0200">A study conducted on hospitalised COVID-19 patients (n = 298) in Guangdong Province, China between January 11, 2020 to February 11, 2020 reported that there was no difference in viral clearance time between patients who received antiviral therapy (LPVr or favipiravir, 15 days, IQR 10–19) and those who did not receive antiviral therapy (14 days, IQR 10–19). 10.7% were admitted to intensive care with no mortality was recorded.
        <xref rid="bib13" ref-type="bibr">
         <sup>13</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0090">
       <label>•</label>
       <p id="p0205">A randomized, open-label trial comparing LPV/r vs standard care in adult patients (n = 199) hospitalised with severe COVID-19 demonstrated LPV/r treatment did not significantly accelerate clinical improvement, reduce mortality, or diminish throat viral RNA detectability.
        <xref rid="bib14" ref-type="bibr">
         <sup>14</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0095">
       <label>•</label>
       <p id="p0210">A retrospective cohort study in adults (n = 33) evaluated use of LPV/r with or without umifenovir, and concluded including umifenovir might delay the progression of lung lesions and lower the possibility of respiratory and gastrointestinal transmission.
        <xref rid="bib15" ref-type="bibr">
         <sup>15</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td align="left">Although data on the use of LPV/r (alone or in combination with other antivirals) for COVID-19 treatment is accumulating,
     <xref rid="bib16" ref-type="bibr">16</xref>, 
     <xref rid="bib17" ref-type="bibr">17</xref>, 
     <xref rid="bib18" ref-type="bibr">18</xref> there is a need for more studies to ascertain its safety and clinical benefits in COVID-19 patients.
    </td>
    <td align="left">Extensive drug interaction profile, including with drugs metabolised by CYP3A and CYP2C19</td>
   </tr>
   <tr>
    <td align="left">
     <bold>Remdesivir</bold>
     <break/>
     <bold>Experimental drug for Ebola virus infection</bold>
    </td>
    <td align="left">A broad-spectrum antiviral agent (investigational nucleoside analogue that may block viral nucleotide synthesis to stop viral replication)</td>
    <td align="left">
     <list list-type="simple" id="ulist0020">
      <list-item id="u0100">
       <label>•</label>
       <p id="p0215">
        <italic>In-vitro</italic> studies reported that remdesivir inhibits SARS-CoV-2 replication in Vero E6 cells with EC50 under 100 μM,
        <xref rid="bib19" ref-type="bibr">
         <sup>19</sup>
        </xref> and it acts by inhibiting RNA synthesis'
        <xref rid="bib20" ref-type="bibr">
         <sup>20</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0105">
       <label>•</label>
       <p id="p0220">A small non-controlled study on compassionate use of remdesivir reported clinical improvement in hospitalised patients
        <xref rid="bib21" ref-type="bibr">
         <sup>21</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0110">
       <label>•</label>
       <p id="p0225">A phase 3 randomized, open-label trial aiming to evaluate safety and efficacy of remdesivir in patients with moderate COVID-19 (n = 600) compared with standard care has begun recruiting patients.
        <xref rid="bib22" ref-type="bibr">
         <sup>22</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td align="left">Several randomised clinical trials evaluating safety and efficacy are being conducted.</td>
    <td/>
   </tr>
   <tr>
    <td align="left">
     <bold>Camostat mesilate/nafamostat mesilate</bold>
     <break/>
     <bold>Treatment for pancreatitis</bold>
    </td>
    <td align="left">Serine protease/TMPRSS2 inhibitor</td>
    <td align="left">
     <list list-type="simple" id="ulist0025">
      <list-item id="u0115">
       <label>•</label>
       <p id="p0230">In mice, camostat mesilate dosed at concentrations akin to the clinically achievable concentration in humans reduced mortality following SARS-CoV infection from 100% to 30–35%.</p>
      </list-item>
      <list-item id="u0120">
       <label>•</label>
       <p id="p0235">
        <italic>In vitro</italic> studies demonstrated that camostat mesilate can block SARS-COV-2 entry into human lung cells through inhibition of a host enzyme (TMPRSS2) that the virus uses to fuse with host cell membranes.
        <xref rid="bib7" ref-type="bibr">
         <sup>7</sup>
        </xref> However, there is no sufficient data to support the use of this drug to treat COVID-19 in clinical practice.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left">A randomized, placebo-controlled trial exploring the impact of camostat mesilate on COVID-19 Infection has begun recruiting patients (n = 180) to provide key insights into the safety of camostat mesilate in COVID-19 patients.</td>
    <td/>
   </tr>
   <tr>
    <td align="left">
     <bold>Favipiravir (favilavir)</bold>
     <break/>
     <bold>Approved drug for novel influenza</bold>
    </td>
    <td align="left">Inhibitor of viral RNA-dependent RNA polymerase, causing chain termination and preventing RNA elongation</td>
    <td align="left">
     <list list-type="simple" id="ulist0030">
      <list-item id="u0125">
       <label>•</label>
       <p id="p0240">An open level non-randomized study comparing the effects of favipiravir (FPV) plus IFN-α by aerosol inhalation (n = 35) versus lopinavir/ritonavir (LPV/r) plus IFN-α by aerosol inhalation (n = 45) in COVID-19 patients showed significantly better treatment effects of FPV in terms of disease progression and viral clearance.
        <xref rid="bib23" ref-type="bibr">
         <sup>23</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0130">
       <label>•</label>
       <p id="p0245">A randomized open-label multicentre trial involving adult patients with COVID-19 (n = 240) aimed at exploring the efficacy of conventional therapy plus umifenovir (n = 120) versus conventional therapy plus favipiravir (n = 120) revealed no significant difference (P = 0.1396) in clinical recovery rate between favipiravir (71/116) and umifenovir (62/120) at Day 7.
        <xref rid="bib24" ref-type="bibr">
         <sup>24</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td align="left">Several randomised clinical trials evaluating the safety and efficacy of this drug are being conducted.</td>
    <td/>
   </tr>
   <tr>
    <td colspan="4" align="left">
     <bold>Antimicrobials with potential activity against SARS-CoV-2</bold>
    </td>
    <td/>
   </tr>
   <tr>
    <td align="left">
     <bold>Azithromycin</bold>
     <break/>
     <bold>Antibacterial agent</bold>
    </td>
    <td align="left">A macrolide antibiotic with some 
     <italic>in vitro</italic> activity against influenza A, H1N1, Zika viruses
     <xref rid="bib25" ref-type="bibr">25</xref>, 
     <xref rid="bib26" ref-type="bibr">26</xref>, 
     <xref rid="bib27" ref-type="bibr">27</xref> and some immunomodulatory and anti-inflammatory effects. It may prevent bacterial superinfection.
    </td>
    <td align="left">
     <list list-type="simple" id="ulist0035">
      <list-item id="u0135">
       <label>•</label>
       <p id="p0250">It has been used as adjunct therapy in the treatment of viral respiratory tract infections such as influenza,
        <xref rid="bib28" ref-type="bibr">
         <sup>28</sup>
        </xref>
        <sup>,</sup>
        <xref rid="bib29" ref-type="bibr">
         <sup>29</sup>
        </xref> albeit with contradictory evidence.
        <xref rid="bib30" ref-type="bibr">
         <sup>30</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0140">
       <label>•</label>
       <p id="p0255">A retrospective, single-centre case series of hospitalised COVID-19 patients (n = 138) used azithromycin for antibacterial coverage,
        <xref rid="bib31" ref-type="bibr">
         <sup>31</sup>
        </xref> although the available evidence is insufficient to establish safety and benefit of adjunct azithromycin use in patients with COVID-19.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left">Risk of cardiac arrhythmias (such as QT prolongation) and psychiatric disturbances</td>
    <td align="left">Azithromycin causes additive toxicity with amiodarone hydrochloride</td>
   </tr>
   <tr>
    <td align="left">
     <bold>Chloroquine</bold>
     <break/>
     <bold>Antimalarial agent</bold>
    </td>
    <td align="left">May interfere with ACE2 receptor glycosylation thus preventing SARS-CoV-2 binding to target cells
     <xref rid="bib32" ref-type="bibr">
      <sup>32</sup>
     </xref>
    </td>
    <td align="left">
     <list list-type="simple" id="ulist0040">
      <list-item id="u0145">
       <label>•</label>
       <p id="p0260">Chloroquine is active against various viruses including SARS-CoV-2
        <xref rid="bib33" ref-type="bibr">33</xref>, 
        <xref rid="bib34" ref-type="bibr">34</xref>, 
        <xref rid="bib35" ref-type="bibr">35</xref> and reported to have immunomodulatory activity.
        <xref rid="bib32" ref-type="bibr">
         <sup>32</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0150">
       <label>•</label>
       <p id="p0265">Currently, limited data and clinical experience is available to substantiate the efficacy and possible benefits of chloroquine in patients with COVID-19.
        <xref rid="bib36" ref-type="bibr">
         <sup>36</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0155">
       <label>•</label>
       <p id="p0270">Although the pharmacokinetics and toxicity profile of chloroquine is well-established in malaria treatment (the use of high dose for short period or low dose for longer duration),
        <xref rid="bib32" ref-type="bibr">
         <sup>32</sup>
        </xref> additional data are needed to determine optimal dose and duration as well as toxicity profile when used in patients with COVID-19.
       </p>
      </list-item>
     </list>
    </td>
    <td align="left">Risk of cardiac arrhythmias, retinal damage (long term use); caution in patients with glucose-6-phosphate-dehdrogenase deficiency and diabetic patients.</td>
    <td align="left">Chloroquine may increase ciclosporin's concentration and risk of toxicity (creatinine concentration may increase even with low doses of ciclosporin); cimetidine reduces metabolism of chloroquine</td>
   </tr>
   <tr>
    <td align="left">
     <bold>Hydroxychloroquine</bold>
    </td>
    <td align="left">Hydroxychloroquine (hydroxyl analog of chloroquine) has similar antiviral mechanism as chloroquine.
     <xref rid="bib37" ref-type="bibr">
      <sup>37</sup>
     </xref>
     <break/>This may include inhibition of viral enzymes or processes and ACE2 cellular receptor inhibition.
    </td>
    <td align="left">
     <list list-type="simple" id="ulist0045">
      <list-item id="u0160">
       <label>•</label>
       <p id="p0275">Hydroxychloroquine is also active against SARS-CoV-2
        <xref rid="bib33" ref-type="bibr">
         <sup>33</sup>
        </xref>
        <sup>,</sup>
        <xref rid="bib34" ref-type="bibr">
         <sup>34</sup>
        </xref> and, unlike chloroquine, is better tolerated when used at high doses for longer duration.
        <xref rid="bib32" ref-type="bibr">
         <sup>32</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0165">
       <label>•</label>
       <p id="p0280">However, multiple clinical trials have already been initiated across the globe
        <xref rid="bib38" ref-type="bibr">
         <sup>38</sup>
        </xref> and early findings from China reported good prognosis for patients who received hydroxychloroquine sulfate 400 mg daily for 5 days.
        <xref rid="bib39" ref-type="bibr">
         <sup>39</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0170">
       <label>•</label>
       <p id="p0285">A randomized, controlled open-label trial compared the efficacy of standard treatment (oxygen therapy, antiviral agents, antibacterial agents, and immunoglobulin, with or without corticosteroids) vs standard treatment plus oral hydroxychloroquine in patients in COVID-19 patients (n = 68) from February 4–28, 2020. Time to clinical recovery, body temperature recovery time and the cough remission time were significantly shortened with hydroxychloroquine.
        <xref rid="bib40" ref-type="bibr">
         <sup>40</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0175">
       <label>•</label>
       <p id="p0290">A comparative observational study designed to emulate a randomized clinical trial using real-world data collected from the routine care of hospitalised COVID-19 patients (n = 181) in France compared the efficacy of standard care alone (n = 84) vs standard care plus oral hydroxychloroquine (n = 97) but found no significant difference in admission to ICU or death at day 7 after hospital admission.
        <xref rid="bib41" ref-type="bibr">
         <sup>41</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td align="left">Ocular effects (retinopathy),
     <break/>Rarely, cardiac toxicity, severe hypoglycaemia, agranulocytosis, thrombocytopenia
    </td>
    <td align="left">Have relatively better drug interaction profile compared with chloroquine, but it may interact with drugs affecting blood glucose concentration</td>
   </tr>
   <tr>
    <td align="left">
     <bold>Hydroxychloroquine with azithromycin</bold>
    </td>
    <td align="left">See above for information about each agent.</td>
    <td align="left">
     <list list-type="simple" id="ulist0050">
      <list-item id="u0180">
       <label>•</label>
       <p id="p0295">Preliminary findings from a small nonrandomized study showed that patients (n = 36) who received hydroxychloroquine with azithromycin had a higher percentage of negative PCR results in nasopharyngeal samples at day 6 than those who received hydroxychloroquine alone.
        <xref rid="bib36" ref-type="bibr">
         <sup>36</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0185">
       <label>•</label>
       <p id="p0300">A pilot uncontrolled non-comparative observational study in Marseille, France investigated the efficacy of hydroxychloroquine with azithromycin in mild COVID-19 patients (n = 80), and revealed that all except two patients (1 death, and 1 severe case) improved clinically at Day5.
        <xref rid="bib42" ref-type="bibr">
         <sup>42</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0190">
       <label>•</label>
       <p id="p0305">While early research is promising, data is very limited, and more work is required to assess the clinical benefits and safety profile of this drug combination.</p>
      </list-item>
      <list-item id="u0195">
       <label>•</label>
       <p id="p0310">Emerging evidence suggests that the combination could have a severe QT prolongation, highlighting the need to do adequate cardiac assessment, especially coexisting conditions and use of other drugs causing QT prolongation.
        <xref rid="bib43" ref-type="bibr">
         <sup>43</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0200">
       <label>•</label>
       <p id="p0315">Another study recently reported that azithromycin used alone has caused QT prolongation,
        <xref rid="bib44" ref-type="bibr">
         <sup>44</sup>
        </xref> demonstrating the need for more evidence to clear the confusion in relation to the use of this combination drug and to understand the actual cause of the QT prolongation
       </p>
      </list-item>
      <list-item id="u0205">
       <label>•</label>
       <p id="p0320">Sarayani et al. (2020) analysed data from FDA's Adverse Event Reporting System (more than 13 million cases), and concluded that Hydroxychloroquine/chloroquine use was not associated with a safety signal while azithromycin used alone was associated with TdP/QT prolongation.</p>
      </list-item>
     </list>
    </td>
    <td align="left">See above for information about each agent. Both drugs are associated with QT prolongation,
     <xref rid="bib45" ref-type="bibr">
      <sup>45</sup>
     </xref> raising concerns regarding the safety of this drug combination.
    </td>
    <td align="left">See above for information about each agent.</td>
   </tr>
   <tr>
    <td colspan="3" align="left">
     <bold>Other agents</bold>
     <xref rid="tbl1fnb" ref-type="table-fn">b</xref>
    </td>
    <td/>
    <td/>
   </tr>
   <tr>
    <td align="left">
     <bold>Ibuprofen and other NSAIDS</bold>
    </td>
    <td align="left">
     <list list-type="simple" id="ulist0055">
      <list-item id="u0210">
       <label>•</label>
       <p id="p0325">A letter published in The Lancet Respir Med
        <xref rid="bib46" ref-type="bibr">
         <sup>46</sup>
        </xref> reported a link between use of thiazolidinediones and ibuprofen and an increased ACE2 expression, resulting in worsened outcomes in COVID-19 patients. However, as of April 1, there is no compelling published evidence to support an association between ibuprofen and poor outcomes in patients diagnosed with COVID-19.
       </p>
      </list-item>
      <list-item id="u0215">
       <label>•</label>
       <p id="p0330">On March 18, the WHO communicated, via Twitter, that there is lack of strong evidence on this issue and that it does not recommend against the use of ibuprofen.</p>
      </list-item>
      <list-item id="u0220">
       <label>•</label>
       <p id="p0335">Similarly, the US FDA issued a statement on March 19 that all NSAIDS, through reducing inflammation and fever, may affect the utility of diagnostic symptoms in detecting infections, but there is no scientific evidence connecting these drugs with worsening of COVID-19 symptoms.</p>
      </list-item>
     </list>
    </td>
    <td align="left">GI ulceration or bleeding; salt and fluid retention, hypertension
     <break/>Renal impairment, hyperkalaemia, heart failure
    </td>
    <td align="left">NSAIDs may reduce antihypertensive effect of ACEIs and may increase risk of renal impairment and hyperkalaemia</td>
    <td/>
   </tr>
   <tr>
    <td align="left">
     <bold>ACE Inhibitors and Angiotensin II Receptor Blockers (ARBs)</bold>
    </td>
    <td align="left">
     <list list-type="simple" id="ulist0060">
      <list-item id="u0225">
       <label>•</label>
       <p id="p0340">It is hypothesised that because human pathogenic coronaviruses bind to their target cells through ACE2,
        <xref rid="bib46" ref-type="bibr">46</xref>, 
        <xref rid="bib47" ref-type="bibr">47</xref>, 
        <xref rid="bib48" ref-type="bibr">48</xref> increased expression of ACE2, facilitated by ACE inhibitors or ARBs, may potentially worsen COVID-19 infections.
        <xref rid="bib46" ref-type="bibr">
         <sup>46</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0230">
       <label>•</label>
       <p id="p0345">Conversely, it has also been hypothesised that the use of ACEIs/ARBs could be beneficial if given to patients with COVID-19, particularly in those ACEI/ARB naïve patients.
        <xref rid="bib49" ref-type="bibr">
         <sup>49</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0235">
       <label>•</label>
       <p id="p0350">There remains a lack of conclusive evidence on the benefit or harm of these drugs in COVID-19 infection. Continuation of treatment with ACE inhibitors or ARBs is recommended for patients who are currently prescribed such agents.
        <xref rid="bib50" ref-type="bibr">
         <sup>50</sup>
        </xref>
        <sup>,</sup>
        <xref rid="bib51" ref-type="bibr">
         <sup>51</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td align="left">Renal impairment, hyperkalaemia, angioedema, hypotension, persistent cough</td>
    <td align="left">
     <sup>Interacts with NSAIDs, increasing the risk of hyperkalaemia and renal impairment</sup>
    </td>
    <td/>
   </tr>
   <tr>
    <td align="left">
     <bold>Nitric oxide (inhaled)</bold>
    </td>
    <td align="left">A selective pulmonary vasodilator with demonstrated benefit in the treatment of acute respiratory distress syndrome (ARDS), one of the serious complications of COVID-19.
     <xref rid="bib52" ref-type="bibr">
      <sup>52</sup>
     </xref>
    </td>
    <td align="left">
     <list list-type="simple" id="ulist0065">
      <list-item id="u0240">
       <label>•</label>
       <p id="p0355">There is in 
        <italic>vitro</italic> evidence of direct antiviral activity of nitric oxide against SARS-CoV.
        <xref rid="bib53" ref-type="bibr">
         <sup>53</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0245">
       <label>•</label>
       <p id="p0360">Clinical trials evaluating the use of inhaled nitric oxide in the management of mild-to-moderate COVID-19 are underway.
        <xref rid="bib54" ref-type="bibr">
         <sup>54</sup>
        </xref>
       </p>
      </list-item>
      <list-item id="u0250">
       <label>•</label>
       <p id="p0365">At this time there is no strong evidence to support its use clinically for COVID-19</p>
      </list-item>
     </list>
    </td>
    <td align="left">Thrombocytopenia, hypokalaemia, hyperbilirubinemia</td>
    <td align="left">Its effect could be increased by sildenafil, leading to severe drug interactions, although there is only anecdotal evidence</td>
   </tr>
   <tr>
    <td align="left">
     <bold>Ivermectin</bold>
    </td>
    <td align="left">Anti-parasitic drug with anti-viral activity. Has a nuclear transport inhibitory activity may be effective against SARS-CoV-2</td>
    <td align="left">
     <list list-type="simple" id="ulist0070">
      <list-item id="u0255">
       <label>•</label>
       <p id="p0370">An 
        <italic>in vitro</italic> study showed a potential for ivermectin against SARS-CoV-2.
        <xref rid="bib55" ref-type="bibr">
         <sup>55</sup>
        </xref>
       </p>
      </list-item>
     </list>
    </td>
    <td align="left">Safe at a dose for anti-parasitic use, but from 
     <italic>in vitro</italic> study and IC50 it is not possible to achieve the required SARS-CoV-2 IC50 (2μM) even with 3 times the highest dose approved for ivermectin. Clinical safety data at these doses is not available.
    </td>
    <td align="left">Relatively safe from drug interactions point of view</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tbl1fna">
   <label>a</label>
   <p id="ntpara0010">Other antivirals active against influenza viruses such as baloxavir
    <xref rid="bib56" ref-type="bibr">
     <sup>56</sup>
    </xref> and neuraminidase inhibitors (oseltamivir)
    <xref rid="bib57" ref-type="bibr">
     <sup>57</sup>
    </xref> are currently under investigation for potential use in the treatment of COVID-19.
   </p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tbl1fnb">
   <label>b</label>
   <p id="ntpara0015">Other drugs currently being evaluated for potential use in the management of patients hospitalised with severe COVID-19 include disease-modifying anti-rheumatic drugs such as sarilumab, immunosuppressive agents such as sirolimus, general corticosteroids, and high dose ascorbic acid. 
    <bold>NB: The information contained in the table is emerging and rapidly evolving and reflects the evidence at the time of writing this piece (April 25, 2020)</bold>.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
